1. Introduction: Observed System Behavior In the UK pharmaceutical market, commercial discussions often begin with sales performance and market share. Yet NHS Primary Care prescribing data contains monthly signals that are not forecasts; they are observed system behavior. By the time commercial data hardens the narrative, prescribing patterns have often already evolved. The advantage lies not in reacting faster, but in recognizing change earlier. 2. Commercial Movement vs. Be

Portfolio strategy in healthcare is fundamentally different from portfolio strategy in most other industries.   Decisions are not driven by short-term sales signals or commercial noise, but by long-term direct prescribing behavior,  sustainability, and healthcare system dynamics . This is where Merlinn plays a distinct role. From “Is this worth exploring?” to “Is this structurally meaningful?” Portfolio teams are often asked difficult questions early in the decision process:

🔷How Market Access Teams work with Merlinn Insights How do you track the real-world impact of your access decisions post-launch? Closing the gap between clinical evidence and healthcare system realities is essential — not only to secure access, but to ensure it remains sustainable over time. This visual illustrates how Market Access teams use tools like Merlinn Insights to transform NHS primary care prescribing data into strategic understanding, helping keep access decisions

🟢 How Commercial and Supply Planning Teams Read Demand Behavior with Merlinn In healthcare planning, the biggest risks rarely come from execution. They come from early demand assumptions that quietly lose validity over time. Production, procurement, and supply decisions are often made months in advance — long before demand has fully settled. Interpreting early signals responsibly, without overreacting, is therefore critical. In this article, I share how Merlinn is used to ma

👁️‍🗨️𝗕𝗲𝘆𝗼𝗻𝗱 𝗣𝗮𝗿𝘁𝗻𝗲𝗿 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁𝘀: 𝗥𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗕𝗹𝗶𝗻𝗱 𝗦𝗽𝗼𝘁𝘀 𝗶𝗻 𝗖𝗗𝗠𝗢 𝗖𝗮𝗽𝗮𝗰𝗶𝘁𝘆 𝗣𝗹𝗮𝗻𝗻𝗶𝗻𝗴 𝗜𝗻 𝘁𝗵𝗲 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺, 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗮𝗿𝗲 𝗼𝗳𝘁𝗲𝗻 𝗮𝗻𝗰𝗵𝗼𝗿𝗲𝗱 𝗶𝗻 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗳𝗼𝗿𝗲𝗰𝗮𝘀𝘁𝘀 𝗮𝗻𝗱 𝘄𝗵𝗼𝗹𝗲𝘀𝗮𝗹𝗲 𝗱𝗮𝘁𝗮. 𝗬𝗲𝘁 𝗯𝘆 𝘁𝗵𝗲 𝘁𝗶𝗺𝗲 𝘁𝗵𝗲𝘀𝗲 𝘀𝗶𝗴𝗻𝗮𝗹𝘀 𝗳𝘂𝗹𝗹𝘆 𝘀𝘂𝗿𝗳𝗮𝗰𝗲, 𝘁𝗵�

🔷𝐖𝐡𝐲 𝐝𝐨 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐝𝐚𝐬𝐡𝐛𝐨𝐚𝐫𝐝𝐬 𝐚𝐥𝐰𝐚𝐲𝐬 𝐬𝐡𝐨𝐰 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐨𝐨 𝐥𝐚𝐭𝐞? Data availability in Pharma is rarely the problem. The real challenge is 𝐭𝐢𝐦𝐢𝐧𝐠. Many leadership teams are surprised by "sudden" market shifts, not because the data wasn't there, but because they were looking at the 𝐰𝐫𝐨𝐧𝐠 𝐬𝐢𝐠𝐧𝐚𝐥. We tend to focus on 𝐏𝐫𝐞𝐬𝐜𝐫𝐢𝐛𝐢𝐧𝐠 𝐏𝐚𝐭𝐭𝐞𝐫𝐧𝐬 (what happened), when we should be analyzing 𝐏𝐫𝐞𝐬𝐜𝐫𝐢𝐛𝐢𝐧

𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐚𝐫𝐞 𝐨𝐟𝐭𝐞𝐧 𝐦𝐚𝐝𝐞 𝐥𝐨𝐧𝐠 𝐛𝐞𝐟𝐨𝐫𝐞 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧 𝐛𝐞𝐠𝐢𝐧𝐬. At this stage, the key questions are 𝐧𝐨𝐭 𝐚𝐛𝐨𝐮𝐭 𝐭𝐚𝐜𝐭𝐢𝐜𝐬, but about 𝐰𝐡𝐞𝐭𝐡𝐞𝐫 𝐝𝐞𝐦𝐚𝐧𝐝 𝐢𝐬 𝐬𝐭𝐚𝐛𝐥𝐞, 𝐡𝐨𝐰 𝐛𝐞𝐡𝐚𝐯𝐢𝐨𝐮𝐫 𝐞𝐯𝐨𝐥𝐯𝐞𝐬 𝐨𝐯𝐞𝐫 𝐭𝐢𝐦𝐞, and 𝐰𝐡𝐞𝐫𝐞 𝐮𝐧𝐜𝐞𝐫𝐭𝐚𝐢𝐧𝐭𝐲 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐥𝐢𝐞𝐬. In this article, I explain how 𝐌𝐞𝐫𝐥𝐢𝐧𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯

In many industries, understanding demand starts with sales.   In healthcare, it starts with prescribing. Sales figures, stock movements, or distribution data may describe commercial activity, but   they do not explain how medicines are actually used across the healthcare system .   Prescribing behavio is where system needs, professional judgement, and real-world usage come together. This is why   NHS primary care prescribing data matters . It reflects   real-world usage patte